Bendamustine-Brentuximab: Bridging to Transplant
نویسندگان
چکیده
منابع مشابه
Bridging to Transplant in Diffuse Large B Cell Lymphoma
Non-Hodgkin lymphoma (NHL) is the eighth most common malignancy worldwide. Diffuse large B cell lymphoma (DLBCL) is the most frequent subtype, accounting for >30% of NHL cases. Advances in novel approaches in the last two decades, such as immunotherapy with rituximab, have achieved improvements in terms of overall and long-term survival rates. The current standard of care for the firstline trea...
متن کاملComplete response to brentuximab vedotin in a transplant-naïve patient with relapsed CD30-positive nodular lymphocyte-predominant Hodgkin lymphoma.
644.8. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lympho-cyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by theGerman Hodgkin Lymphoma Study Group (GHSG). Blood. 2008;111:109-111.9. Advani RH, Horning SJ, Hoppe RT, et al. Frontline therapy of nodularlymphocyte predominant Hodgkin lymphoma with rituximab: the StanfordUniversi...
متن کاملPost-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation.
Advances in haploidentical bone marrow transplantation (h-BMT) have drastically broadened the treatment options for patients requiring BMT. The possibility of significantly reducing the complications resulting from graft-versus-host disease (GvHD) with the administration of post-transplant cyclophosphamide (PT-CY) has substantially improved the efficacy and applicability of T cell-replete h-BMT...
متن کاملBrentuximab Vedotin (SGN-35).
Brentuximab vedotin (SGN-35) is an antibody-drug conjugate (ADC) directed against the CD30 antigen expressed on Hodgkin lymphoma and anaplastic large cell lymphoma. SGN-35 consists of the cAC10 chimerized IgG1 monoclonal antibody SGN30, modified by the addition of a valine-citrulline dipeptide linker to permit attachment of the potent inhibitor of microtubule polymerization monomethylauristatin...
متن کاملBlood Spotlight Brentuximab vedotin
Delivery of cytotoxic agents specifically to malignant cells has always been a goal of cancer therapy. With the development of monoclonal antibodies for clinical use, this goal has become a reality, and antibody-drug conjugates are now part of standard therapy in diseases such as lymphoma and breast cancer. Brentuximab vedotin, which targets CD30, has contributed to the success of antibody-drug...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biology of Blood and Marrow Transplantation
سال: 2015
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2014.11.498